Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Assets (2016 - 2025)

Integra Lifesciences Holdings' Current Assets history spans 17 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 7.2% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, up 7.2%, while the annual FY2025 figure was $1.2 billion, 7.2% up from the prior year.
  • Current Assets for Q4 2025 was $1.2 billion at Integra Lifesciences Holdings, up from $1.1 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.4 billion in Q1 2024 and bottomed at $1.0 billion in Q3 2023.
  • The 5-year median for Current Assets is $1.1 billion (2021), against an average of $1.1 billion.
  • The largest annual shift saw Current Assets skyrocketed 37.51% in 2024 before it decreased 21.79% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.2 billion in 2021, then rose by 0.67% to $1.2 billion in 2022, then decreased by 8.91% to $1.1 billion in 2023, then increased by 2.23% to $1.1 billion in 2024, then rose by 7.2% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Current Assets are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).